Metabolomx Receives Grant for Lung Cancer Detection Technology
A Mountain View, CA-based diagnostic company Metabolomx has declared that the National Cancer Institute has provided the company with a small business innovation research (SBIR) grant worth $1.14 million.
The Phase 1/11 fast track SBIR contract will be directed towards the R&D of the sensor array system for the detection of lung cancer. The proprietary Metabolomx lung detection technology can identify the molecular fingerprint of the cancer by using a sampling of metabolites obtained from exhaled breath. The developed system is being studied at the Cleveland Clinic in a lung cancer screening study.
The Chief Executive Officer of Metabolomx, Dr Paul Rhodes stated that active tumors produce tiny molecule metabolites, which can be found in exhaled breath. The cancer detection system developed by Metabolomx is a non-invasive system that can facilitate an early detection of the cancer. Dr Rhodes expressed gratitude for the grant received from the cancer institute stating that it will help in validating the technology for breath analysis for various cancers that include breast cancer, lung cancer and colon cancer.
Metabolomx has discovered the breath test for cancer and owns all worldwide rights for the same. The company has used the expertise of professionals in the field of biological and artificial sensor arrays, product development and neural processing. The technology enables quick, non-invasive, cost effective and early identification of lung and other cancers.
Please use one of the following formats to cite this article in your essay, paper or report:
APA
Choi, Andy. (2022, July 20). Metabolomx Receives Grant for Lung Cancer Detection Technology. AZoSensors. Retrieved on September 14, 2025 from https://www.azosensors.com/news.aspx?newsID=3464.
MLA
Choi, Andy. "Metabolomx Receives Grant for Lung Cancer Detection Technology". AZoSensors. 14 September 2025. <https://www.azosensors.com/news.aspx?newsID=3464>.
Chicago
Choi, Andy. "Metabolomx Receives Grant for Lung Cancer Detection Technology". AZoSensors. https://www.azosensors.com/news.aspx?newsID=3464. (accessed September 14, 2025).
Harvard
Choi, Andy. 2022. Metabolomx Receives Grant for Lung Cancer Detection Technology. AZoSensors, viewed 14 September 2025, https://www.azosensors.com/news.aspx?newsID=3464.
We're committed to providing free access to quality science. By registering and providing insight into
your preferences you're joining a community of over 1m science interested individuals and help us to
provide you with insightful content whilst keeping our service free.
or
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.